First Health Pharmaceuticals B.V.
C. Willem Houck has a diverse work experience, spanning various industries and roles. C. Willem currently serves as the Chief Executive Officer at First Health Pharmaceuticals B.V., leading the company's advancements in the field of advanced RNA biochemistry. C. Willem is also the Director of Post-ICU, a digital journal for tomorrow.
In the past, Houck has held key positions such as Managing Director at Girasol NY, where they focused on healthcare and technology business innovation. C. Willem also served as Director at Bandall, specializing in commercializing products in the North American market. Furthermore, they were the Chief Executive Officer at DEARhealth, a fast-growing scale-up that revolutionizes chronic disease management.
Houck's experience also includes being the Director at NICO.LAB, where they aimed to empower physicians and revolutionize emergency care through the integration of human and artificial intelligence. C. Willem held a Director role at Health Care Financial Exchange Inc and played a pivotal role at StartUp Health as a Healthcare Transformer, providing coaching and support to startups in the healthcare industry.
Houck is the Founder of iDx Ventures and has also served as the President of DaklaPack Europe, where they successfully established contracts for DaklaPack US, a provider of consumer healthcare fulfillment services.
C. Willem Houck's education history is as follows:
C. Willem began their education at Leiden University in 1985, where they pursued a Master of Laws (LL.M.) degree in the field of Law. C. Willem successfully completed their studies in 1991.
In 1991, they attended HEC Paris and obtained an MBA degree, specializing in Strategic Marketing. This program lasted for one year, concluding in 1992.
In 2001, they enrolled in a Senior Executive Education program at INSEAD. Although the degree obtained is unspecified, it is known that they completed this program the same year.
In 2005, they participated in another Senior Executive Education program at IMD (International Institute for Management Development) - Business Programs. The specific degree earned in this program is not stated.
This person is not in any teams
This person is not in any offices
First Health Pharmaceuticals B.V.
First Health Pharmaceuticals B.V. is a biotech company with its main offices in Amsterdam, the Netherlands. Considering the groundbreaking nature of the RNA Helicase targeting technology, developed by our group, and the vast array of pathogens and malignancies that is targeted by our compounds, it will come as no surprise that many research groups worldwide, directly or indirectly, participated in the research in our field of interest. Some of these collaborations are based on a joint development agreement but most academic groups performed efficacy tests related to pathogens that fit their field of research purely for academic reasons. These collaborations are of mutual benefit. Our research group is the only one in the world that developed a large portfolio of small molecule DDX3 Helicase inhibitors, for use both as antivirals and anti tumor agents. As such, many highly specialised research groups around the world are interested in testing our compounds, in order to gain more insight in the complex cellular RNA helicase biochemistry, related to the pathogens they are working on. We, from our side, also learn many new things about our field of research, but even in cases in which no direct benefit is to be expected for our company, we still aim to satisfy all requests that reach us from interested academic groups. Please visit our website for more information: http://firsthealthpharma.com/